Based on our results, patients with IBD showing a reduction in IL-6 from baseline to 10 weeks of biologic therapy have a 4.7-fold higher probability of achieving a clinical response at 12 months of biologic therapy compared to patients with no IL-6 reduction. Here, IL6 is linked to irritable bowel syndrome.